Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NuBloom vs Somi Health

NuBloom
Graded #134

Higher grade

vs+0.29999999999999716
Somi Health
Graded #141

Lower grade

The verdict

NuBloom takes it — 69/100 to 68.7/100, but only just.

NuBloom grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuBloom is a women's metabolic-health telehealth practice founded by family and integrative-medicine physician Dr. Somi Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuBloom +6
72
66
Dose & formulationSomi Health +21
54
75
Clinical oversightEven
82
82
Labs & monitoringNuBloom +8
61
53
FulfillmentNuBloom +9
85
76
Contract termsNuBloom +8
55
47
NuBloom · left barSomi Health · right bar

The numbers

MetricNuBloomSomi Health
WeighScore69/10068.7/100
GradeCC
Scorecard rank#134#141
Semaglutide$149/mo (2.4 mg dose, compounded)$135/mo (starting dose, compounded)
Tirzepatide$279/mo (15 mg dose, compounded)$165/mo (starting dose, compounded)
Coverage49 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
NuBloom

Graded #134 · C

Strengths

  • Transparent, openly published pricing: compounded semaglutide $149/mo and tirzepatide $279/mo as flexible month-to-month subscriptions
  • Founded and medically led by a named physician (Dr. Marianne Pinkston Mueller, family/integrative medicine, 25+ years)
  • Whole-person model pairs GLP-1s with hormone, gut-health and longevity care plus in-depth lab testing
  • State coverage published openly: 49 states listed on the site (all except Mississippi)
  • Optional 90-day 1:1 coaching program with weekly meetings and unlimited text support ($599/mo)

Where it loses points

  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • NuBloom's own LegitScript/PCAB status is not displayed; only its telehealth partner is certified
  • Compounded medications are not FDA-approved; one FAQ loosely calls them 'FDA-approved,' contradicting the product pages
  • All sales are final and medical consult fees are non-refundable; no returns on prescription products
  • Disputes go to binding individual arbitration; the Terms' governing-law state is left as an unfilled '[STATE]' placeholder
Somi Health

Graded #141 · C

Strengths

  • Among the lowest compounded prices: semaglutide $135/mo, tirzepatide $165/mo (3-month plan)
  • Oral semaglutide tablet option for those who want no injections
  • One price at any dose, with the medical visit and shipping included
  • LegitScript Approved seal displayed; partnered with 503A pharmacies
  • Free 2-5 day shipping; no insurance required

Where it loses points

  • Compounded only - no brand-name Wegovy, Zepbound, Ozempic or Mounjaro
  • Homepage advertises a 100% money-back guarantee but Terms state all sales are final, no refunds on medication
  • Partner pharmacies are not individually named (material transparency gap)
  • No single prescribing medical group named; only affiliated professional entities
  • State availability not published; confirmed only during intake

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard